Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Introduction: Once-weekly (OW) subcutaneous (s.c.) semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. This trial was designed to assess the pharmacokinetics, safety and tolerability of OW s.c. semaglutide in healthy Chinese subjects.M...
| Published in: | Advances in Therapy Vol. 38; no. 1; pp. 550 - 562 |
|---|---|
| Main Authors: | , , , , , |
| Format: | clinical trial research randomized controlled trial Journal Article |
| Published: |
Springer Nature
2021
|
| Online Access: | View this record in EBSCOhost |